The purpose of this paper is to investigate the relationship between factors affecting the decision to purchase and the need for innovative pharmaceutical products by the Thai pharmaceutical industry. An orally disintegrating tablet (ODT) is an example of an incremental pharmaceutical innovative product which is still a new concept in Thailand. The results show that inancial factors, as well as government policy and drug regulations, have a positive effect on the purchasing decision of pharmaceutical excipients for ODT from the Thai pharmaceutical industry.
INTRODUCTION
The Thai pharmaceutical industry is currently being hampered from importing pharmaceutical products because of social expectations, consumer responsibility, encouragement, cost of research and development, quality assurance, and the regulatory and registration procedures of Thailand's Food and Drug Administration (Thai FDA). The Thai pharmaceutical industry is confronted with a decrease in the value of the country's domestic pharmaceutical products compared to imports. Moreover, there are many threats from the cooperation of Southeast Asian countries, resulting in ASEAN harmonization in many areas, such as with the Pharmaceutical Inspection Cooperation Scheme in Good Manufacturing Practice (PIC/s GMP) and the proliferation of transnational drug companies in Thailand due to the Free Trade Agreement (FTA) between Thailand and the United States of America for business bene it. This phenomenon has led to the closure of many domestic businesses.
Nonetheless, technological changes in the pharmaceutical industry have a signi icant in luence on innovation (Malerba, 2002) . Advancement in pharmaceutical innovation involves two components: active pharmaceutical ingredients (API) and pharmaceutical excipients. API are chemicals used for curing and alleviating diseases. The development of API takes time, with at least 16 years being necessary for the completion of all phases (Nolan et al., 1980) . In Thailand, there has never been complete API development due to the high cost and time required. Thus, in Thailand, the development of an innovative pharmaceutical product should emphasize pharmaceutical excipients since they have a greater potential for success than API.
However, there is no evidence to suggest that the Thai pharmaceutical industry will adopt such an innovative product. Thus, the purpose of this paper is to investigate which factors affect the decision to purchase innovative pharmaceutical excipients from the Thai pharmaceutical industry by using pharmaceutical excipients for ODT as the case study. The factors affecting the decision to purchase an innovative product from the Thai pharmaceutical industry are investigated and discussed. Thus, this research can be used as a guideline for assessing the purchasing decision of the Thai pharmaceutical industry toward other pharmaceutical innovative products.
This research is divided into six sections, the irst of which provides an introduction. Secondly, an explanation of the background to ODT and the factors inluencing the purchasing decision are reviewed. The third section outlines the methodology used to develop and validate the conceptual framework. The fourth section provides the results of the purchase intention and the factors affecting the decision to purchase an innovative product from the Thai pharmaceutical industry. The ifth section provides the results and discusses the factors affecting the decision to purchase, focusing on ive components. Finally, the last section concludes the research indings and proposes ideas for future research.
Literature Review
Innovative products are unlikely to be successful in the marketplace due to a lack of customers demand. Thus, whether or not the pharmaceutical industry in Thailand should adopt innovative products is an interesting topic. In this section, the background to ODT, and factors affecting the decision to purchase an innovative product are reviewed.
Orally disintegrating tablet (ODT)
The ODT is in oral dosage form, immediately dissolving or disintegrating in the mouth without water or other liquids (Watanabe et al., 1995) . According to the United States Pharmacopeia 41 (USP41) and the National Formulary 36 (NF36), the ODT tablet must take no longer than one minute to dissolve, depending on the design and composition of the formula. The ODT is suitable for bed-ridden patients, children, the elderly, or psychotic patients (Nagar et al., 2011) . It also elevates the patient's compliance since it can be taken without water. The ODT formula comprises only active pharmaceutical ingredients (API) and suitable pharmaceutical excipients.
Active pharmaceutical ingredient (API)
API is a speci ic chemical for the purpose, with no special ODT requirement. In general, researchers use several drugs to produce ODT, such as anticonvulsants, antibiotics, analgesics, diuretics, neuroleptics, as well as antidiarrheal, anticancer, and heart disease medication.
Pharmaceutical excipients for ODT
The development of ODT by direct compression involves specially designed pharmaceutical excipients to reduce disintegration time. Therefore, inding alternative pharmaceutical excipients for ODT is very important.
Factors affecting the decision to purchase an innovative product
A review of the available literature reveals various factors affecting the decision to purchase an innovative product, as summarised in Table 1. The literature review highlighted a lack of research on the identifying factors affecting the decision to purchase innovative products in the Thai pharmaceutical industry. Therefore, this study proposes a conceptual framework for investigating this aspect, consisting of ive components: 1) inancial factors, 2) marketing factors, 3) production factors, 4) innovation factors, and 5) government policy and drug regulation factors, with the following hypotheses.
H1: Financial factors are affecting the decision to purchase an innovative product in the Thai pharmaceutical industry H2: Marketing factors are affecting the decision to purchase an innovative product in the Thai pharmaceutical industry H3: Production factors are affecting the decision to purchase an innovative product in the Thai pharmaceutical industry H4: Innovation factors are affecting the decision to purchase an innovative product in the Thai pharmaceutical industry H5: Government policy and drug regulation factors are affecting the decision to purchase an innovative product in the Thai pharmaceutical industry (Ekelund and Persson, 2003) A. et al. (1991) Marketing Factors Need for the product The market needs pharmaceutical excipients for ODT (Nolan et al., 1980; A. and J, 1995; Abbott, 1995) Patient compliance Pharmaceutical excipients for ODT enhance patient compliance (Chauhan and Mason, 2008) Continued on next page (Nolan et al., 1980) Size of the target market Pharmaceutical excipients for ODT have a large target market (Manchanda and Honka, 2005) Advertising costs Pharmaceutical excipients for ODT can reduce advertising costs (Manchanda and Honka, 2005; Liu and Gupta, 2012) Distribution channels Pharmaceutical excipients for ODT have many distribution channels (Liu and Gupta, 2012; Malerba, 2002) Reduce production errors Pharmaceutical excipients for ODT help to reduce errors in production (Curieux-Belfond et al., 2009; Gilmore and Smith, 1996; Lawrence, 2008) Save time in production Pharmaceutical excipients for ODT help to reduce production time (Curieux-Belfond et al., 2009; Gilmore and Smith, 1996; Lawrence, 2008) Innovation Factors New knowledge acquisition Pharmaceutical industries will acquire new knowledge through the use of pharmaceutical excipients for ODT (DiMasi et al., 2003; A. and J, 1995; Cardinal, 2001) Capable of representing other products in the industry Pharmaceutical excipients for ODT have the capability to represent other products in the industry (Malerba, 2002) Capable of developing their own patent Pharmaceutical excipients for ODT have the ability to develop their own patent for the pharmaceutical industry (Nolan et al., 1980; Grabowski et al., 2002) Continued on next page (Grabowski, 1989; DiMasi et al., 2003; Grabowski et al., 2002) Reduce failure in new product development Pharmaceutical excipients for ODT help to reduce failure in new product development (Malerba, 2002; Alkhateeb et al., 2009) Value-added to the product Pharmaceutical excipients for ODT help to add value to new products (Hsieh and Sloan, 2008) Government policy and drug regulation factors FDA approval in drug registration Pharmaceutical excipients for ODT ensure drug registration approval by the FDA (Kola and Landis, 2004; Danzon and Chao, 2000) Financial support policy The government has set a inancial support policy regarding pharmaceutical excipients for ODT (Maynard and Bloor, 2003) Tax reduction policy The government has set a tax reduction policy regarding pharmaceutical excipients for ODT (Kyle, 2007) Technological transfers Agreement between the government and pharmaceutical industry regarding pharmaceutical excipients for ODT (Maynard and Bloor, 2003) Agreement between the government and pharmaceutical industry Agreement between the government and pharmaceutical industry regarding pharmaceutical excipients for ODT Pharmaceutical standards and safety Pharmaceutical standards and safety ensure to use pharmaceutical excipients for ODT (Grabowski et al., 1978) The conceptual framework for investigating ive hypotheis is shown inFigure 1. 
MATERIALS AND METHODS

Data collection
A survey questionnaire involving pharmacists currently working in the Thai pharmaceutical industry was used as the method for collecting data by purposive sampling. The quantitative method was applied to reduce bias. The questionnaires were distributed to respondent pharmacists from a list issued by the Thai FDA. The questionnaires were in the Thai language and consisted of four parts: 1) demographics and basic data on the respondents, 2) corporate data consisting of general information on companies and sales and products, 3) a ive-point Likert scale rating of ive factors, each consisting of six indicators, with a total of 30 questions, and 4) open-ended remarks and suggestions. The questionnaire was validated by three experts in the pharmaceutical ield using the index of item-objective congruence (IOC). The data from the questionnaire was collected and analysed using a ive-point Likert scale. The questionnaire was sent directly to participants in paper and online format. The factors were calculated using multiple regression SPSS version 22. The raw data was examined via factor analysis, correlation analysis, reliability analysis, and regression analysis.
Variables and measurements
Independent variables: the independent variables consist of ive factors: inancial, marketing, production, innovation, as well as government policy and drug regulation. The independent variables were measured using a ive-point Likert scale.
Dependent variable: the decision to purchase is the dependent variable. The dependent variables were measured using a ive-point Likert scale.
Validity and reliability analysis
In this research, the collected data was measured for reliability and validity. Validity is the degree to which the test measures what it is supposed to measure. Reliability refers to the stability and consistency of the measurement. Factor analysis was used to assess the validity and produce a set of observable variables.
The research was validated by sending the questionnaire to three experts in the pharmaceutical ield. All experts gave their comments, which led to the modi ication and improvement of the questionnaire.
The consistency method was applied to measure the reliability of this research. Cronbach's alpha coef icient was used to test reliability, with a value of 0.6 considered acceptable, and 0.8 and above indicating a high level of reliability.
Correlation and regression analysis
Respondents were requested to consider each factor in the questionnaire, consisting of six indicators. The average score for each indicator was then calculated. Pearson correlation was performed to identify the relationship between the inancial, marketing, production, innovation as well as government policy and drug regulation factors. Multiple regression analysis was also performed to test the ive hypotheses concerning the decision to purchase an innovative product.
RESULTS AND DISCUSSION
Demographics of respondents
The demographic characteristics of the respondents include education, job position, duration of business, type of business, type of irm, business income, and a number of employees. The results are shown in Table 2 .
Validity and reliability analysis
The purpose of validity and reliability analysis is to ensure the results are free from random errors. In this study, the IOC is performed by specialists. All questions have an IOC of between 0.6-1.0, implying that the variables are valid. Consistency testing is examined by Cronbach's alpha coef icient, ranging from 0 to 1. The higher the Cronbach's alpha coef icient, the greater the reliability. The analysis is shown in Table 3 , indicating that the questionnaire is a reliable instrument for measuring the variables.
Correlation analysis of variables
Pearson correlation is used to identify the correlation between inancial, marketing, production, in- Decision to purchase an innovative product 0.730 novation, as well as government policy and drug regulation factors. A correlation coef icient ranging from 0.10 to 0.29 is considered weak, 0.30 to 0.49 medium, and 0.50 to 1.0 strong. However, to avoid multicollinearity, the correlation coef icient should not go above 0.8 (Wang and Benbasat, 2007) . Positive correlation represents that one variable increases or decreases in line with another. Conversely, a negative correlation means that one variable does not increase or decrease in line with another. The results of this study show that there is no multicollinearity. There is a correlation between innovation and marketing factors, indicating a positive effect (0.273). Innovation and production factors have a negative relationship (-0.285). The correlation matrix is shown in Table 4 .
Multiple regression analysis
Multiple regression analysis is conducted on the model with data manipulation used to remove outliers. From the original 192 respondents, 185 remained in the sample after removal of the outliers. Correlation analysis is employed to test the interaction between variables, whereas regression analysis is conducted to test hypotheses H 1 , H 2 , H 3 , H 4, and H 5 . The correlations are shown in Table 5 . The enter method is used for multiple regression analysis. The model shows a good it with a p-value of 0.000 (which is not greater than 0.05). The collinearity adjustment R 2 is 30.90%. Hypothesis 1: H1 posits that a relationship exists between inancial factors and the decision to purchase (p = 0.000). Its p-value is under 0.05, positing that H1 is strongly supported. The results of the tests reveal (Beta = 0.458, t = 7.106) that the decision to purchase an innovative product is a major determinant. Hypothesis 2: H2 shows that marketing factors are not related to the decision to purchase (p = 0.482). The data in Table 5 (Beta = -0.046 and t = -0.704) indicates that marketing factors have an insigni icant effect on the decision to purchase an innovative product.
Hypothesis testing
Hypothesis 3: H3 exhibits that production factors do not have a signi icant relationship with the decision to purchase (p = 0.615). The data in Table 5 (Beta = 0.034, t = 0.504) indicates that production factors do not affect the decision to purchase an innovative product.
Hypothesis 4: H4 reveals that the relationship between innovation factors and the decision to purchase is insigni icant (p = 0.073). Variables in the equation (Beta = 0.058, t = 0.854) indicate that the decision to purchase does not substantiate the results of other studies on innovation factors.
Hypothesis 5: H5 displays that government policy and drug regulation factors have a relationship with the decision to purchase (p = 0.006). Its p-value is under 0.05, from which it can be concluded that H5 is supported. In addition, from the indings Beta = 0.180 and t = 2.757, it can be concluded that the decision to purchase is less likely when the effect of government policy and drug regulation factors increases.
From the indings, it can be concluded that the factors affecting the decision to purchase are inancial and also relate to government policy and drug regulation. Financial and government policy and drug regulation factors are shown to have a positive effect on the decision to purchase with a standardised coef icient of 0.458 and 0.180, respectively.
Factors affecting the decision to purchase an innovative product in the Thai pharmaceutical industry were based on multiple regression and assessed using SPSS software version 22, where the established model was found to be acceptable. Details of the factors are described below:
Financial factors
Financial factors were found to be the most important, and have a positive effect on the decision to purchase an innovative product from the Thai pharmaceutical industry. This is no surprise since it conirms the experts' opinion that most pharmaceutical companies would prefer a reduction in the cost of pharmaceutical excipients. It also concurs with the suggestion by Wiggins (1991) that the cost of capital affects product validity. This is also similar to other industries in that the cheaper the raw materials, the greater the pro it.
Marketing factors
Marketing factors were found to be insigni icant. (Nolan et al., 1980) state that a decrease in marketing may result in increased costs for developing new drugs, leading to more safety regulations, which may prolong the time interval between patenting and marketing. However, according to the interviews with experts, marketing may impact on the consumer but was not shown to be important to the manufacturer since drug sales in Thailand are not in luenced by users but by law and regulation or governance.
Production factors
Production factors were not found to be signi icant. Pharmaceutical production of tablets involves milling, mixing, granulating, drying, and tableting (Lawrence, 2008) . Lawrence also states that critical raw material attributes, process parameters, and design space lead to product development. If there are fewer production steps, the production time is also reduced. However, some respondents reported that there are various problems affecting production time as well as production steps, such as out of service machinery or human error.
Innovation factors
Innovation factors were found to be insigni icant. (Hsieh and Sloan, 2008) investigated the adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan, inding that overall, the adoption of pharmaceutical product innovation is worth the increased cost of new drugs. The respondents commented that Thai patients paid little attention or were unaware of innovation since they did not feel it was important to them or had no usefulness. However, the government should encourage and emphasise the advantages of innovation by providing more knowledge to the public.
Government policy and drug regulationfactors
Government policy and drug regulation factors were ranked second in affecting the decision to purchase an innovative product from the Thai pharmaceutical industry. (Danzon and Chao, 2000) reported that generic drug competition has a significantly negative effect on free price regulation in the United States, United Kingdom, Germany, and Canada, whereas, in countries with strict price regulation such as France, Italy, and Japan, the number of generic competitors has either no effect or a positive effect on prices. In Thailand, price competition and drug registration are controlled, speci ically in relation to pharmaceutical products regulated by the Thai FDA. These regulations in luence the registration of pharmaceutical products. Hospitals are the biggest buyers of pharmaceutical products and must follow the regulations of the FDA. Hence, government policy and drug regulation factors affect the decision to buy ODT products from the pharmaceutical industry, as also con irmed by experts.
The results from respondents show that they decided to purchase pharmaceutical excipients for ODT, with an average score of 4.56 from 5.00 (S.D.= 1.82). This suggests that the price of an innovative product is extremely relevant to Thai people because their importance has not been emphasized. They suggest that good technological exploitation should incorporate the government, private sector, and small, medium-sized enterprises. However, there are many barriers to technological exploitation, such as the amount of supporting data needed to convince authorities concerning the laws and regulations of the FDA and ensure con idence in the quality of drugs in Thailand.
CONCLUSIONS
Pharmaceutical excipients for ODT still represent a new concept in Thailand. However, there is no research identifying factors affecting the purchasing decision regarding pharmaceutical excipients for ODT. This study investigates the relationship between ive factors: inancial, marketing, production, innovation as well as government policy and drug regulation, and the decision to purchase from the Thai pharmaceutical industry. The results are ranked in order of importance, with inancial factors (beta = 0.458) and government policy and drug regulationfactors (beta = 0.180), being irst and second, respectively. The prototype of pharmaceutical excipients for ODT is considered in relation to costs, pro its, and meeting the registration criteria of the Thai FDA. Respondents are interested in pharmaceutical excipients for ODT, which has the potential to adopt this innovation into the market.
